Date: 2015-10-15
Type of information: Nomination
Compound:
Company: Delcath Systems (USA - NY)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On October 6, 2015, Delcath Systems, a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announced that Jennifer K. Simpson, Ph.D., MSN, CRNP, the company\'s President and CEO, has been appointed to its Board of Directors, effective October 1, 2015. In addition, Roger G. Stoll, Ph.D., formerly Executive Chairman, was appointed as Chairman of the Board. With Dr. Simpson\'s appointment, Delcath Systems will have seven directors.
Financial terms:
Latest news:
